Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment
- PMID: 16204691
- DOI: 10.1093/jnci/dji289
Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment
Abstract
Background: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually to provide information on cancer rates and trends in the United States. This year's report updates statistics on the 15 most common cancers in the five major racial/ethnic populations in the United States for 1992-2002 and features population-based trends in cancer treatment.
Methods: The NCI, the CDC, and the NAACCR provided information on cancer cases, and the CDC provided information on cancer deaths. Reported incidence and death rates were age-adjusted to the 2000 U.S. standard population, annual percent change in rates for fixed intervals was estimated by linear regression, and annual percent change in trends was estimated with joinpoint regression analysis. Population-based treatment data were derived from the Surveillance, Epidemiology, and End Results (SEER) Program registries, SEER-Medicare linked databases, and NCI Patterns of Care/Quality of Care studies.
Results: Among men, the incidence rates for all cancer sites combined were stable from 1995 through 2002. Among women, the incidence rates increased by 0.3% annually from 1987 through 2002. Death rates in men and women combined decreased by 1.1% annually from 1993 through 2002 for all cancer sites combined and also for many of the 15 most common cancers. Among women, lung cancer death rates increased from 1995 through 2002, but lung cancer incidence rates stabilized from 1998 through 2002. Although results of cancer treatment studies suggest that much of contemporary cancer treatment for selected cancers is consistent with evidence-based guidelines, they also point to geographic, racial, economic, and age-related disparities in cancer treatment.
Conclusions: Cancer death rates for all cancer sites combined and for many common cancers have declined at the same time as the dissemination of guideline-based treatment into the community has increased, although this progress is not shared equally across all racial and ethnic populations. Data from population-based cancer registries, supplemented by linkage with administrative databases, are an important resource for monitoring the quality of cancer treatment. Use of this cancer surveillance system, along with new developments in medical informatics and electronic medical records, may facilitate monitoring of the translation of basic science and clinical advances to cancer prevention, detection, and uniformly high quality of care in all areas and populations of the United States.
Similar articles
-
Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival.Cancer. 2004 Jul 1;101(1):3-27. doi: 10.1002/cncr.20288. Cancer. 2004. PMID: 15221985
-
Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. doi: 10.1093/jnci/djg040. J Natl Cancer Inst. 2003. PMID: 12953083 Review.
-
Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations.Cancer. 2006 Oct 15;107(8):1711-42. doi: 10.1002/cncr.22193. Cancer. 2006. PMID: 16958083
-
Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer.Cancer. 2014 May 1;120(9):1290-314. doi: 10.1002/cncr.28509. Epub 2013 Dec 16. Cancer. 2014. PMID: 24343171 Free PMC article.
-
Epidemiology of cancer among Hispanics in the United States.J Natl Cancer Inst Monogr. 1995;(18):17-28. J Natl Cancer Inst Monogr. 1995. PMID: 8562218 Review.
Cited by
-
Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.J Clin Oncol. 2013 Mar 20;31(9):1134-9. doi: 10.1200/JCO.2012.42.7252. Epub 2013 Feb 19. J Clin Oncol. 2013. PMID: 23423747 Free PMC article.
-
Metformin targets ovarian cancer stem cells in vitro and in vivo.Gynecol Oncol. 2012 Nov;127(2):390-7. doi: 10.1016/j.ygyno.2012.07.115. Epub 2012 Aug 2. Gynecol Oncol. 2012. PMID: 22864111 Free PMC article.
-
Incidence and Mortality Risks of Cancer in Patients with Type 2 Diabetes: A Retrospective Study in Shanghai, China.Int J Environ Res Public Health. 2016 Jun 3;13(6):559. doi: 10.3390/ijerph13060559. Int J Environ Res Public Health. 2016. PMID: 27271648 Free PMC article.
-
MicroRNA Profiling of the Effect of the Heptapeptide Angiotensin-(1-7) in A549 Lung Tumor Cells Reveals a Role for miRNA149-3p in Cellular Migration Processes.PLoS One. 2016 Sep 6;11(9):e0162094. doi: 10.1371/journal.pone.0162094. eCollection 2016. PLoS One. 2016. PMID: 27598578 Free PMC article.
-
Opposite roles of LPA1 and LPA3 on cell motile and invasive activities of pancreatic cancer cells.Tumour Biol. 2012 Oct;33(5):1739-44. doi: 10.1007/s13277-012-0433-0. Epub 2012 Jun 8. Tumour Biol. 2012. PMID: 22678979
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources